http://rdf.ncbi.nlm.nih.gov/pubchem/reference/6161063

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 2468
issn 1534-4681
1068-9265
issueIdentifier 4
pageRange 2456-2468
publicationName Annals of Surgical Oncology
startingPage 2456
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_91971ecdaa283b47e61430a483338a53
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_279e3f4e484b8da8ec7a1708bfbbb0a4
bibliographicCitation Hill CS, Rosati LM, Hu C, Fu W, Sehgal S, Hacker-Prietz A, Wolfgang CL, Weiss MJ, Burkhart RA, Hruban RH, De Jesus-Acosta A, Le DT, Zheng L, Laheru DA, He J, Narang AK, Herman JM. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Annals of Surgical Oncology. 2022 Feb 07;29(4):2456–68. doi: 10.1245/s10434-021-11202-8.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d8130d58184c8482fb24c7d0eba969e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9577a631cf8abbef6b33896779bfd8f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d51889e7fd27302ddc99523b40844ee
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a3665c31218d2845327ed34e72d3337
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_30568d7ec2fdbe01d571e2fb64d72396
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e32df9413ee7f4af9bcceab8dd197a12
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78a0bc9404748946a67369d397c89ffb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fbb1460cea97746d6c2b53f66e0f2751
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac417f02618a4598cca1056503c8e6b7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4672-1981
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e35ca2b6399f55d4c972ef77a6b08059
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58464759a5d39b657fef03482bfeaabf
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_91f6bc4827d1984f6d2ca4b9f44b98b4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69837d45a93e4b3d61cfff8aaf374f42
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52805a712003a1d9ba8ff80a1ec5ed3c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_202f58f4db0eb40499457c3b4ffb0da6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_56439a9bdab226c0e05d5eddb36b775e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1943bf8f1921d5ac80167c14065e4bf
date 2022-02-07^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/35129721
https://pubmed.ncbi.nlm.nih.gov/PMC8933354
https://doi.org/10.1245/s10434-021-11202-8
isPartOf https://portal.issn.org/resource/ISSN/1534-4681
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8578
https://portal.issn.org/resource/ISSN/1068-9265
language English
source https://scigraph.springernature.com/
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000230Q000473
http://id.nlm.nih.gov/mesh/D016634
http://id.nlm.nih.gov/mesh/D010190Q000473
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D020360
http://id.nlm.nih.gov/mesh/D012189
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8766
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795

Showing number of triples: 1 to 53 of 53.